MEDICINE DETAILS
Pifeltro
Active ingredient: Doravirine
Pifeltro is recorded in this directory with the active ingredient Doravirine. This page brings together catalogue strength, dosage-form and pack records so they can be checked against a prescription.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Pifeltro used for?
Pifeltro (doravirine) is a prescription medicine indicated to treat adults with human immunodeficiency virus type 1 (HIV-1) infection. It is used in combination with other antiretroviral medicines.
Pifeltro is not suitable for HIV-infected patients who are resistant to medicines in the same class (non-nucleoside reverse transcriptase inhibitors or NNRTIs).
It is available in tablet form, each containing 100 mg doravirine.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Pifeltro identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
100 mg · 30 tablets Catalogue organisation: MSD Sharp & Dohme GmbH
-
100 mg film-coated tablets · 90 tablets Catalogue organisation: Abacus Medicine A/S
OFFICIAL SOURCES
Check the Pifeltro record at an official source.
Search for “Pifeltro” or “Doravirine”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Pifeltro.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Pifeltro
01What is Pifeltro?＋
This directory record associates the brand name Pifeltro with the active ingredient Doravirine. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Pifeltro strengths and packs are recorded?＋
The catalogue currently shows: 100 mg · 30 tablets; 100 mg film-coated tablets · 90 tablets. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Pifeltro?＋
Catalogue records currently name: MSD Sharp & Dohme GmbH, Abacus Medicine A/S. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Pifeltro?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Pifeltro, payment request, stock guarantee or binding offer.
06Can I buy Pifeltro from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.